News & Updates
Filter by Specialty:
HK data: SGLT2 inhibitors cut risks of respiratory and renal diseases in T2DM
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risks of respiratory and renal diseases vs dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM), researchers from the University of Hong Kong (HKU) have reported.
HK data: SGLT2 inhibitors cut risks of respiratory and renal diseases in T2DM
29 Mar 2023
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
Combination therapy with metformin and thiazolidinedione appears to be the best performing glucose-lowering medication for preventing atrial fibrillation (AF) in patients with type 2 diabetes (T2D), as shown in a study.
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
24 Mar 2023
Time-restricted eating offers no additional benefits in adults with obesity, NAFLD
Time-restricted eating does not appear to be more effective than daily calorie restriction in terms of improving intrahepatic triglyceride content, body fat, and metabolic risk factors for adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to a study.
Time-restricted eating offers no additional benefits in adults with obesity, NAFLD
24 Mar 2023
Cinnamon helps improve lipid profile
The polyphenol-rich spice cinnamon has the potential to modulate imbalances in lipid profile for certain individuals with metabolic disorders, particularly those with polycystic ovarian syndrome, according to the results of an umbrella meta-analysis.
Cinnamon helps improve lipid profile
23 Mar 2023
Coordinated care improves use of CVD-preventive therapies in T2D
A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.